RevolutionizingPrecision
Heart CareIngenuity Applied

HeartFlow brings together
human ingenuity and advanced
technology to help combat
heart disease, the leading causeof death.
HeartFlow's non-invasive,
personalized cardiac test provides
unprecedented visualization ofeach patient’s coronary arteries,
enabling physicians to create more
effective treatment plans fortheir patients.

Superior Quality
By combining review from trained analysts,
who have over 500,000 hours of collective
experience, with AI-powered algorithms
trained on millions of CT images, HeartFlow
is bringing a new level of precision tonon-invasive detection of heart disease.

»2x more likely to identify
disease than other tests¹»

Low false negative and false
positive rates reported inreal-world clinical use²»

“Core Lab” quality control
monitoring program with over
10,000 measurements²

Clinical Excellence
Since inception, HeartFlow has been committed to producing comprehensive clinicalevidence supporting the diagnostic accuracy, safety, efficacy, cost-effectiveness, andutility of its product portfolio.
With more than 425 publications in prominent peer-reviewed medical journals including
JAMA, JACC, Circulation, the American Journal of Cardiology, and Heart, the HeartFlow
technology has been proven across diverse patient populations. These clinical activities
have included a series of large, multi-center global trials.

ROBUST EVIDENCE» 16 company-sponsored clinical trials and registries addressing
accuracy and outcomes» 100+ investigator-initiated studies» 425+ peer-reviewed publications» Demonstrated safety with long-term data out to 5 years» Studied in > 10,000 patients

Exceptional Clinical Results
Time and time again, HeartFlow demonstrates unmatched non-invasive diagnostic
performance and accuracy, alongside cost-effectiveness and efficacy.

83% of avoidable coronary
angiograms cancelled4

40% reduction inlayered testing5

Higher diagnostic accuracy
than other common
non-invasive cardiac tests³

36% improvement
in revascularization
efficiency5

Dominates stress testing
and CTA alone in costeffectiveness analysis, better
outcomes at lower costs6$2.7B annual cost savings
delivered to CMS throughreduction of invasive
diagnostic procedures4

Areas of Research
HeartFlow is committed to ongoing research and is interested in exploring the useof FFRCT in these populations:

Coronary Applications

Other Applications• Pre-TAVR• Neurovascular• Acute Coronary Syndrome(ACS) - NSTEMI• Renovascular• Heart Transplant• PAD• Emergency Department• Perioperative CardiacEvaluation• Preventative Screening• Pediatrics

Best-in-class Technology»
»
»
»
»
»
»
»

Patient-specific Interactive 3D Model
Best-in-class medical image analysis
Advanced deep learning (AI) methodology
to precisely extract coronary anatomy
AI trained on millions of CT images
carefully annotated by expert analysts
Physics-based computational models
assess pressure and flow changes incoronary arteries
HIPAA and SOC 2 Type II compliant,HITRUST certified
Secure cloud infrastructure, including
encrypted transmission of image dataand protected health information (PHI)
Comprehensive IP portfolio of > 400
issued and allowed patents worldwide,
covering innovations in cardiovascular
medicine, physiology and bioengineering

0.67

Unparalleled Innovation
As CAD diagnosis increasingly moves to a CTA-led pathway, HeartFlow is developing
a comprehensive, integrated solution to help physicians deliver precise, personalized
diagnoses and optimize treatment for their patients.

Anatomic
Stenosis*

Physiology & Myocardial
Blood Flow^

Diagnosis

Plaque*Intervention
Planning

Treatment Optimization
Risk and Prognosis* Currently in development and not available for clinical use. ^ Images not representative of actual product.

Outstanding Customer Experience
FAST

ECONOMICAL<4 hour*
turnaround time²

No inventory orcapital purchase

SEAMLESS
IT integrations
streamline workflows

CustomerExperience

SECURE
Ongoing security andsoftware updates

EDUCATIONSUPPORT

CTA programand image quality
training resources

Dedicated team tofacilitate optimized
reimbursement*Median turnaround time. March 2021

About HeartFlow» Secured regulatory clearance tocommercialize first-of-kind, AI-enabled,
non-invasive diagnostic simulationof FFRCT(2011: CE Mark, 2014: US FDA De NovoClearance, 2016: Japan PMDA approval)» Established Medicare New Technology

Ambulatory Payment Classification toreimburse hospitals, effective Jan 1, 2018

» 96% of people in the US have insurance
coverage for HeartFlow» 100,000+ patients have received aHeartFlow Analysis» Adopted by more than 400 hospitals

worldwide, including 80% of the top 50
heart hospitals in the US7

REFERENCES
1. Nørgaard, et al. Euro J Radiol 2015. Jung, et al. Euro Heart J 2008. Melikian, et al. JACC
Cardiovasc Interv 2010. Koo, et al. JACC 2011. Min, et al. J Am Med Assoc 2012.
Nørgaard, et al. JACC 2014. Danad, et al. JAMA Cardiol 2017. Driessen, et al. JACC 2019.
2. Data on file at HeartFlow. November 2020.
3. Driessen, et al. J Am Coll Cardiol 2019. Nørgaard, et al. J Am Cardiol 2014.
4. Douglas, et al. J Am Coll Cardiol 2016.
5. Curzen, et al. TCTConnect 2020.
6. Karády, et al. JAMA Network Open 2020.
7. Top 50 Heart Hospitals as designated by US News and World Report, 2020-2021.

106759345 v3© 2021 HeartFlow, Inc. | HeartFlow and the HeartFlow logo, CT-Flow and the
CT-Flow logo are among trademarks of HeartFlow, Inc.
www.heartflow.com | 1400 Seaport Blvd., Building B | Redwood City, CA 94063